ARTRYA®
Coronary Artery Disease.
We see you.

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PERTH, Australia, 20 November 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that John Konstantopoulos, Co-Founder and CEO will provide a presentation on the Company to investors attending the Canaccord Genuity, MedTech, Diagnostics and Digital Health & Services Forum in New York, U.S. on 20 November 2025 (U.S. time).

This forum will bring together leading industry thought leaders and the investment community and includes follow on meetings with attending investors. Canaccord Genuity is an independent investment bank with offices around the world, including the U.S. and Australia.

A copy of the Presentation is attached.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit **www.artrya.com** or follow us on LinkedIn at **www.linkedin.com/company/artrya**

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

ARTRYA®

(ASX: AYA)

2025 Canaccord Healthcare Conference

Presentation

Advancing Commercialisation



Important Notice

IMPORTANT NOTICE AND DISCLAIMER

These presentation materials have been prepared by Artrya Limited (**Artrya** or **Company**). By receiving the Presentation Materials, you acknowledge and represent to the Company that you have read, understood and accepted the terms of this disclaimer. You must read this important notice before you attempt to access the Presentation Materials. The information on this page is not part of the Presentation Materials. If you do not understand it, you should consult your professional adviser without delay.

NOT AN OFFER

These Presentation Materials are for information purposes only. The Presentation Materials do not comprise a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law.

The Presentation Materials also do not constitute or form part of any invitation, offer for sale or subscription or any solicitation for any offer to buy or subscribe for any securities nor shall they or any part of them form the basis of or be relied upon in connection therewith or act as any inducement to enter into any contract or commitment with respect to securities. In particular, these Presentation Materials do not constitute an offer to sell or a solicitation to buy, securities in the United States of America. In particular, these Presentation Materials may not be released to U.S. wire services or distributed publicly in the United States.

These Presentation Materials have been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. These Presentation Materials do not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in these Presentation Materials have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable U.S. state securities laws.

The distribution of these Presentation Materials in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. By accepting this document, you represent and warrant that you are entitled to receive such presentation in accordance with the above restrictions and agree to be bound by the limitations contained therein. For further information, see the section titled “International Offer Restrictions”.

NOT INVESTMENT ADVICE

The Presentation Materials are not investment or financial product advice (nor tax, accounting or legal advice) and are not intended to be used for the basis of making an investment decision. Recipients should obtain their own advice before making any investment decision.

SUMMARY INFORMATION

The Presentation Materials do not purport to be all inclusive or to contain all information about the Company or any of the assets, current or future, of the Company.

The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does not purport to contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement or other offering document prepared in accordance with the requirements of Australian law or the laws of any other jurisdiction, including the United States of America.

The Company does not undertake to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

FORWARD LOOKING STATEMENTS

Certain statements contained in the Presentation Materials, including information as to the future financial or operating performance of the Company and its business operations, are forward looking statements. Such forward looking statements:

- are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies;
- involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward-looking statements; and may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social and other conditions.

The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether as a result of new information, future events or results or otherwise.

The words “believe”, “expect”, “anticipate”, “indicate”, “contemplate”, “target”, “plan”, “intends”, “continue”, “budget”, “estimate”, “may”, “will”, “schedule” and similar expressions identify forward looking statements.

All forward looking statements contained in the Presentation Materials are qualified by the foregoing cautionary statements. Recipients are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein.

NO LIABILITY

The Company has prepared the Presentation Materials based on information available to it at the time of preparation. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information, opinions and conclusions contained in the Presentation Materials. To the maximum extent permitted by law, the Company, its related bodies corporate (as that term is defined in the *Corporations Act 2001* (Cth) (**Corporations Act**)) and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including, without limitation, any liability arising from fault or negligence on the part of any person, for any loss arising from the use of the Presentation Materials or its contents or otherwise arising in connection with it.

THIS PRESENTATION HAS BEEN APPROVED FOR RELEASE BY THE BOARD OF ARTRYA LIMITED

NOT FOR RELEASE TO U.S. WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES

Artrya at a Glance – an attractive market and model

Salix® is the only real-time, point of care platform globally delivering end-to-end CCTA assessment

Attractive Market

Commercial Momentum

- (ASX: AYA) - ~AU$550m market cap
- Salix® Platform & Plaque FDA cleared
- Targeted U.S. GTM
- Foundation customers going live, generating revenue, growing pipeline
- Strong balance sheet

Differentiated Product

- Unified CCTA Reporting Platform within 10 mins
- Real-time report, Plaque, and FFRCT[3] analysis
- Streamlines workflow and care

Backed by Leading Institutional Investors:

REGAL FUNDS MANAGEMENT

Wilson Asset Management

PARADICE INVESTMENT MANAGEMENT

1. Company Presentation – slide 7 – Released to ASX on 1 September 2025
2. As of 14 November 2025
3. Salix Coronary Flow not yet cleared by FDA

ARTRYA

What’s broken in coronary diagnosis today

A diagnosis workflow that is slow, burdensome for clinicians, and built for another era

CAD is deadly and common

Plaque goes unseen



Surrogates and symptoms

Long wait times and high uncertainty

Inconclusive results

Unnecessary procedures

The Impact

- Delays in diagnosis and treatment
- Inefficient resource use and higher costs
- Unnecessary invasive procedures

1. CDC – Heart Disease Facts - https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
2. Low Diagnostic Yield of Elective Coronary Angiography. New England Journal of Medicine. March 11, 2010.
3. Temporal Trends in the Frequency of Inducible Myocardial Ischemia During Cardiac Stress Testing. Journal of the American College of Cardiology (JACC). March 12, 2013.
4. Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. JACC. March 2017

ARTRYA

Significant Cardiac CT Growth

Hospitals are under pressure to reduce costs, improve patient care and only have finite resources

Drivers of CCTA Growth

- **Guidelines**: CCTA is now first-line for chest pain[1]
- **Reimbursement in place**: Accelerating adoption[2]
- **CT-First Adoption**: Strong shift to non-invasive testing

Pressures on Hospitals

- CCTA demand is outpacing clinical capacity
- Hospitals need higher throughput
- Delays slow care and increase backlogs

Artrya's Solution - Salix®



1. American College of Cardiology – 2021 AHA/ACC Chest Pain Guideline Perspectives
2. https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta

ARTRYA

Salix® provides streamlined, real-time patient assessment

Clear clinical insights into actionable decisions in minutes



Point of care real-time analysis – without humans

CCTA analysis in under 10 mins increases capacity and throughput

Real-time Plaque and Flow Analysis

Automated assessment of plaque and FFRCT for improved treatment

Unified Reporting Platform

Consolidates CCTA reporting on platform, reduces physician fatigue and reporting costs by consolidating tools

Streamlined Workflow and Enhanced profitability

Improved efficiency, transforms CCTA into a scalable, high-margin service line

* Salix Coronary Flow not yet cleared by FDA

ARTRYA®

From off-site workflows to point of care 10-minute decision

Salix® fits directly into the existing clinical workflow with human intervention

Current approach

Fragmented & off-site



Clinician Orders Assessment

Workstation vendors

Off-site plaque & FFR analysis vendors

Onsite - Manual Assessment

Review & Prepare → CCTA Report → Clinician Finalizes Report

Offsite – 'Human in the loop'

Review, Prepare & Report **Up to 24hrs** → Clinician Receives Report

Manual images upload to offsite provider for workup

Currently

- Inefficient workflow
- Downstream treatment delays

Streamlined approach with Salix®



Point of Care

SALIX®

CCTA Report, Plaque, FFRCT

In 10mins

Clinician Finalizes Report

With Salix®

- Faster throughput
- Faster time to treatment

ARTRYA

Salix® provides a point of care, CCTA reporting platform

Real-time CCTA, Plaque, and Flow[1] analysis from a single platform within 10 minutes







Benefits:

1. Clinician-Controlled, High-Efficiency Analysis
2. Faster triage, standardized reports, streamlined workflow
3. Real-time Plaque and Flow for Personalised Management
4. Enriches Elective PCI pathway
5. Opportunity to scale free-standing Diagnostic and ED[2]

1 Salix Coronary Flow not yet cleared by FDA
2 Study in development to demonstrate results

ARTRYA

Strong value proposition for all stakeholders

Salix® transforms accuracy, efficiency, and patient outcomes across the healthcare ecosystem.

Patients

Faster results and improved outcomes

- Real-time assessment accelerates treatment decisions
- Fewer unnecessary invasive procedures

Clinicians

Integrated workflow speeds reporting and eases clinician workload

- Single platform for CCTA, plaque & FFRCT
- Reduced reading time per study
- Standardised reporting & improved QA



Health Systems

Drive efficiency, increase volumes, and unlocks new revenue opportunities.

- Higher throughput with existing resources
- Increases CCTA volumes
- Enhances elective procedures

Salix® platform roadmap: today, next & future

Real-time modules run on the same Salix® platform, enabling scalable expansion across customers



* Salix Coronary Flow not yet cleared by FDA

ARTRYA

U.S. Market Focus

Commercial pathway for 2026 and beyond

Traction to date

Active in the U.S. market with commercial, clinical, regulatory and capital momentum.

Foundation Customers

- Tanner Health live
- Cone Health and Northeast Georgia Health System following

Strong FDA Progress

- Salix® platform and plaque module FDA-cleared
- Flow module in FDA process.

SAPPHIRE Study

- Multi-site U.S. SAPPHIRE study
- Salix® as new standard of care
- Long term partners

Revenue Growth

- Strong pipeline
- Robust balance sheet
- Establishment of U.S. Footprint

Our Foundational Customers

Tanner Health

Northeast Georgia Health System
Improving the health of our community in all we do

CONE HEALTH

ARTRYA

SAPPHIRE Study: Clinical Overview

Validate the novel Salix® Plaque Dispersion Score (PDS) to risk-stratify patients based on individual plaques and improve treatment decisions.

Overview

To evaluate Salix® PDS as a non-invasive tool for assessing cardiovascular risk, with a specific focus on coronary artery disease in women.

- 3-phased multicentre, retrospective study
- Mass General, Ascension, Piedmont Healthcare, and Huntsville first participants

Key Clinical Outcomes

1. Identify future adverse events with PDS
2. Enable early preventive therapy
3. Improve CAD diagnosis and treatment in women

Study Phases



01 Evidence vs. Standard Care

02 Comparative accuracy vs. invasive imaging

03 Clinical impact of Plaque Dispersion Score

ARTRYA

Our U.S. footprint across leading health systems

Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth.



Mass. General
Massachusetts
12 hospitals
32 Cardiology Centres

Cone Health
North Carolina
5 hospitals
24 Heart Centres

Northeast Georgia Health System
Georgia
5 hospitals
3 Heart Centres

Ascension: Healthcare
94 hospitals
27 Partner Hospital Centres

Huntsville Hospital Health System
Alabama & Tennessee
14 hospitals
19 Heart Centres

Tanner Health
Georgia & Alabama
4 hospitals
5 Heart Centres

Piedmont Healthcare
Georgia & Alabama
25 hospitals
75 Cardiology Centres

ARTRYA

U.S Support Pod
Atlanta, Georgia

Key roles to support foundation customers and Eastern + Southern U.S. operations

SAPPHIRE Study partners

Commercial partners

Outlook: Scaling Salix® in the U.S.

Building commercial momentum, strengthening clinical evidence, and extending product leadership

Drive Commercial Growth

- Accelerate U.S. rollout
- Near term adoption for Platform and Plaque
- Salix® expanding across hospital systems

Clinical & Operational Excellence

- SAPPHIRE Study preparing to launch
- Salix Coronary Flow to be cleared by FDA
- Continue to optimise Cx and Support

Build Scale

- Advance U.S. operational infrastructure
- Execute on the roadmap

ARTRYA

www.artrya.com

John Konstantopoulos
Co-Founder and Chief Executive Officer
+61 8 6478 7816
contact@artrya.com